Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).
Luis Paz‐Ares(Hospital Universitario Virgen del Rocío), Leora Horn(Vanderbilt University), Hossein Borghaei(Fox Chase Cancer Center), David R. Spigel(Sarah Cannon), Martin Steins, Neal Ready(Duke Medical Center), Laura Q.M. Chow(University of Washington), Everett E. Vokes(University of Chicago), Enriqueta Felip(Vall d'Hebron Hospital Universitari), Esther Holgado, Fabrice Barlési(Aix-Marseille Université), Martin Kohlhäeufl(Klinik Schillerhöhe), Óscar Gerardo Arrieta Rodríguez(Instituto Nacional de Cancerología), Marco Angelo Burgio(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Jérôme Fayette(Centre Léon Bérard), Scott Gettinger(Yale University), Christopher Harbison(Bristol-Myers Squibb (United States)), Cécile Dorange(Bristol-Myers Squibb (United States)), Friedrich Graf Finckenstein(Bristol-Myers Squibb (United States)), Julie R. Brahmer(Sidney Kimmel Comprehensive Cancer Center)
Cited by 33
Abstract
LBA109 The full, final text of this abstract will be available at abstracts.asco.org at 2:00 PM (EDT) on Friday, May 29, 2015, and in the Annual Meeting Proceedings online supplement to the June 20, 2015, issue of the Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Saturday edition of ASCO Daily News.
Related Papers
No related papers found
Powered by citation graph analysis